Sign inJoin waitlistJoin the waitlist

Craig Zaidman

Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology · Washington University

Credentials: · ·

History

Washington University School of Medicine
2007–2008
Child Neurology
St Louis Children's Hospital
2004–2007
Washington University/B-JH/SLCH Consortium
2003–2004
Pediatrics
Washington University/B-JH/SLCH Consortium
2001–2003
University of Virginia School of Medicine
1997–2001

Research

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre,…
The Lancet Neurology · 2021 · 399 citations
Peripheral nerve size in normals and patients with polyneuropathy: an ultrasound study
Muscle & Nerve · 2009 · First of 3 authors · Corresponding · 268 citations
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
Nature Medicine · 2022 · 263 citations

Anne Connolly
24 papers
BD
Basil Darras
17 papers
Craig McDonald
17 papers
Jerry Mendell
15 papers
AP
Alan Pestronk
14 papers
Seward Rutkove
10 papers
Susan Iannaccone
9 papers
CP
Crystal Proud
8 papers
JW
Jim Wu
8 papers
John Day
8 papers
Kevin Flanigan
8 papers
Natalie Goedeker
8 papers

Clinical trials

Spinraza in Adult Spinal Muscular Atrophy
Principal investigator · Active not recruiting
Washington University School of Medicine
2018–2025
PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
Site PI · Recruiting · Phase 1, Phase 2
Precision BioSciences, Inc.
2026–2029
Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy
Site PI · Recruiting
Nationwide Children's Hospital
2025–2028
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Site PI · Recruiting · Phase 1, Phase 2
Solid Biosciences Inc.
2024–2031